Immune responses counteract infections and can also cause collateral damage to hosts. We investigated functional outcomes of variation in the rapidly evolving antiviral double-stranded RNA (dsRNA) sensing factor Oligoadenylate Synthetase 1 (OAS1) in primates as a model for understanding how individual immune pathways evolve to minimize deleterious effects on host fitness. Upon binding of dsRNAs, OAS1 polymerizes ATP into 2′-5′ linked oligoadenylate (2-5A), which in turn activates Latent Ribonuclease (RNase L) to kill virus infected cells. OAS1 can undergo auto-activation by host encoded RNAs, raising the question of how it might evolve to mitigate RNase L-mediated cytotoxicity. Using a new yeast-based growth assay, we observed a pattern of frequent loss of 2-5A synthesis by OAS1 from several species. In gorillas, we identified a polymorphism in a conserved substrate binding residue that severely decreases catalytic function. In contrast, lowered 2-5A generation previously associated with variation in humans results from production of unstable OAS1 isoforms. Examination of OAS1 function in monkeys revealed a spectrum of activities, including the complete loss of 2-5A synthesis in tamarins. Frequent loss of catalytic activity in primates suggests that costs associated with OAS1 activation can be so detrimental to host fitness that its pathogen-protective effects are repeatedly forfeited.
INTRODUCTION
The cost of immunity on organismal fitness is distributed among diverse defense functions. A growing collection of studies demonstrate that experimentally induced innate immune activation reduces longevity and fecundity [1] [2] [3] . Related work shows that increased pathogen resistance is often tied to reduced fitness in the absence of infection [4] [5] [6] . It follows that the cost-benefit balance of immune responses fluctuates between species depending on the intensity and frequency of threats from infectious microbes or changes in host biology. These differing histories of exposure can select for increased defense responses in some host lineages and decreased responses in others 7 . How these selective forces might shape the evolution of individual immune pathways remains largely undetermined. Here we investigate diversity in the antiviral Oligoadenylate Synthetase 1 (OAS1)/Latent Ribonuclease (RNase L) pathway in primates as a model system for the evolutionary balance between beneficial and detrimental outcomes of immune functions.
The collateral damage caused by OAS1/RNase L pathway activation provides a useful experimental system for studying the tradeoffs involved in evolution of immune responses. OAS proteins are a critical mediator of innate immunity and function by sensing foreign double-stranded RNA (dsRNA) from invading viruses in the cytosol 8 . Upon dsRNA binding, OAS proteins convert ATP into polymer chains joined by 2′-5′ linkage referred as oligoadenylate (2-5A) 8 . The only reported role for 2-5A is to activate RNase L, which cleaves RNAs at UA/UU dinucleotides 9 . This degradation of viral and host RNAs leads to a potent block of viral replication and eventually apoptosis in infected cells 10 . OAS1 recognizes a general motif of 17 or more base pairs of double stranded RNA with little preference for nucleotide sequence, a pattern frequently occurring in structures within the human transcriptome 11 . Indeed, constitutive editing of cellular dsRNA is required to suppress RNase L induced lethality in cultured human cells, highlighting the active measures taken to protect host cells from the deleterious effects of OAS activation in the absence of infection 12 .
Although OAS1 is the most ancient of the OAS genes, its volatile evolutionary history is consistent with potential costs. Several animal lineages, including insects and teleost fish, have lost OAS1 completely 13 . In contrast, OAS1 has undergone extensive gene amplifications in rodents and even-toed ungulates 14 . In mice, the OAS family has expanded to include eight Oas1 genes (Oas1a-h). Of these OAS1 copies, only two are catalytically active, while OAS1b and OAS1d actively antagonize 2-5A generation through a dominant negative mechanism, highlighting a need to modulate harmful 2-5A levels 15, 16 . OAS1 amino acid sequence is also highly variable across species. Phylogenetic and population genetic analysis demonstrate that OAS1 has evolved under recurrent positive selection in primates and other mammals, resulting in remarkable sequence diversity [17] [18] [19] . A lack of comparative studies of OAS1 activity, however, leaves the functional consequences of OAS1 evolution unknown.
Here we report that OAS1 enzymatic activity is repeatedly and independently lost or reduced among primates. In gorillas, a high frequency variant in a single active-site amino acid position leads to dramatically reduced 2-5A production. In contrast, we show that variation in human OAS1 previously associated with reduced 2-5A levels results from production of protein isoforms with lower stability rather than compromised catalytic capacity. Finally, we identify fixed amino acid substitutions shared in multiple tamarin species OAS1 that eliminate 2-5A production completely. Our findings highlight the cost-benefit conundrum of immune functions on host fitness, where deleterious effects of immune activation may sometimes outweigh the benefits of host defenses.
RESULTS

A yeast growth assay for OAS1/RNase L pathway activity
To investigate functional differences among OAS1 and RNase L variants, we developed an assay to efficiently measure changes in cellular viability resulting from RNase L activation by OAS1 signaling ( Figure 1A ). Budding yeast, which constitutively produce cytosolic dsRNA, are a proven system for studying the function of the dsRNA sensing Protein Kinase R (PKR), where eIF2α phosphorylation by PKR leads to attenuation of protein translation and growth arrest [20] [21] [22] . We tested whether heterologous co-expression of human OAS1 and RNase L might similarly arrest yeast growth due to cellular RNA degradation. While galactose-induced expression of either OAS1 or RNase L alone has no effect, coexpression of both proteins robustly inhibits yeast growth ( Figure 1B ). Furthermore, growth arrest specifically depends on RNase L activation, as yeast expressing OAS1 and a catalytically inactive 23 RNase L H672A grow normally ( Figure 1B ). Growth attenuation also corresponds with ribosomal RNA (rRNA) cleavage and reduced protein translation, a hallmark of RNase L activation 24 ( Figure 1C ). Thus, OAS1/RNase L pathway function is recapitulated when genetically transplanted into yeast cells, providing a versatile new platform to efficiently measure pathway output. 
A high frequency SNP in gorilla OAS1 controls catalytic output
To understand functional diversity of OAS1 in primates, we first compared the p46 isoform cloned from four hominoid species via coexpression with human RNase L in yeast. In developing the yeast assay, we found expression of the OAS1 inhibitor Us11 encoded by Herpes Simplex Virus 1 increases sensitivity and unmasks differences in OAS1 activity between species. Us11 broadly inhibits dsRNA sensing in infected cells by sequestering dsRNA 25, 26 , and lowers OAS1 activity in yeast below the threshold of complete growth arrest (Figure 2A We initially chose to compare the longer p46 isoform to understand how variation in the C-terminus might influence activity. Unexpectedly, OAS1 p46 mRNA cloned from chimpanzee and gorilla fibroblasts harbor early stop codons in exon five or six, respectively, resulting in smaller protein products (Figure 2A /S1B). When expressed in yeast, human, chimpanzee, and orangutan OAS1 similarly activate human RNase L and arrest growth. Yeast expressing gorilla OAS1, however, grow robustly in the presence of Us11 (Figure 2A ). These data suggest that gorilla OAS1 is deficient 2-5A synthesis compared to its hominoid cousins.
To determine the basis of reduced activity in gorilla OAS1, we engineered a series of human-gorilla chimeric OAS1 proteins and tested their ability to activate RNase L in yeast ( Figure S1A ). With this approach, we identified an arginine to cysteine amino acid substitution at codon 130 (R130C) unique to gorilla as a candidate mutation causative of the attenuated phenotype ( Figure S1B ). We next tested the effects of codon 130 mutation in both human and gorilla OAS1. Reversion from cysteine 130 to the ancestral arginine in gorilla OAS1 restored activity to levels similar to other hominoids, while the converse arginine to cysteine substitution in human OAS1 significantly reduced activity as judged by robust yeast growth ( Figure 2B ). The R130C substitution in gorilla OAS1 is therefore responsible for its decreased level of 2-5A synthesis in yeast.
Reduced 2-5A synthesis by gorilla OAS1 might reflect reduced dsRNA binding affinity or reduced catalytic capability. To distinguish between these possibilities, we mapped residue 130 to a previously published crystal structure of OAS1 in complex with ATP analog ApCpp 27 . Consistent with a role in catalysis, Arginine 130 is located in the OAS1 active-site cleft and is highly conserved in mammals ( Figure 2C ). A previous structural study of porcine OAS1 identified hydrogen-bonding between residue 130 (porcine OAS1 residue 129) and the a-phosphate of the acceptor ATP molecule as a critical for proper enzymatic function 27 . To directly test the impact of the R130C mutation on catalytic function, we reconstituted OAS1 activity in vitro with purified proteins ( Figure S3A ). This technique allows for the direct visualization of 2-5A products generated from purified proteins with excess available dsRNA.
Consistent with our observations in yeast, gorilla OAS1 and human OAS1 R130C produce far less 2-5A than wild-type human OAS1 or gorilla OAS1 C130R ( Figure 2D ). Importantly, we confirmed that gorilla RNase L functions equivalently to human RNase L in yeast and is not more sensitive to the enzymatic products of the low activity OAS1 variant ( Figure S4 ), ruling out compensatory co-evolution. Together, these data show that the gorilla OAS1 variant recovered is catalytically impaired by a mutation in a critical active site residue.
Variation in OAS1 has previously been shown to modulate 2-5A production within human populations 28 . Extensive polymorphism also exists in nonhuman primate OAS1 29 , leading us to investigate whether the OAS1 allele we recovered is fixed or variable in gorilla populations. We found evidence for polymorphism by examining a whole-genome sequencing dataset generated from 31 individual gorillas 30 . Among this cohort, the R130C allele occurred at a frequency of 36%, while the remainder encoded the full activity ancestral arginine (Table S1 ). The low activity allele is present in individuals from both eastern and western lowland gorilla subspecies, suggesting an ancient origin.
Western gorillas are estimated to have diverged from eastern gorillas approximately 261 Kya, with some gene flow continuing between the populations until between approximately 77-150 Kya 31, 32 .
Therefore, genetic variation in OAS1 that dramatically reduces its catalytic output has been maintained in gorilla populations for at least 77 thousand years. 
Variation in human OAS1 activity reflects altered isoform stability
Similar to our findings in gorillas, high frequency variation in human OAS1 have been previously associated with decreased 2-5A synthesis. A G/A SNP in the OAS1 exon 6 splice-acceptor (rs10774671) has been strongly associated with variation in human OAS activity due to alternative splicing of the final OAS1 exon. Individuals with the ancestral G allele predominantly produce the p42 and p46 enzymes, and those with the derived A allele produce the p42, p44, p48 and p52 isoforms ( Figure 3A ). OAS1 activity is significantly reduced in individuals with one or two copies of the A allele 28 , leading to speculation that human isoforms differ in catalytic capacity. We investigated the mechanism of decreased 2-5A production from the p44, p48, and p52 isoforms. When expressed in yeast, both p42 and p46 robustly activate RNase L and arrest cell growth. The p44, p48, and p52 OAS1 isoforms, however, only weakly inhibit growth ( Figure 3A ). The expression level of these isoforms is also decreased, correlated with their reduced ability to arrest growth ( Figure 3B ). These results demonstrate that OAS1 isoforms associated with the A genotype are produce less stable proteins, resulting in decreased RNase L activation.
To test whether decreased expression of p44, p48, and p52 in yeast is recapitulated in human cells, we transfected HEK293T cells with expression vector encoding each isoform and measured OAS1 protein level by western blot. While p42, p46, and p48 are robustly expressed, p44 and p52 protein levels are significantly decreased ( Figure 3B ). Consistent with our results, a previous study failed to detect endogenous p44 and p52 isoforms in primary human cells 33 . To ensure the lack of RNase L activation is due to lowered expression, we directly tested enzymatic activity in vitro using equimolar amounts of full length purified protein ( Figure S3B ). Each of the five isoforms is capable of robust 2-5A synthesis with minimal difference between each enzyme ( Figure 3C ). These data indicate that reduced OAS activity in humans with the A allele is best explained by production of unstable isoforms which decrease global OAS1 protein levels and not reduced enzymatic activity of individual isoforms. 
OAS1 activity is variable among monkeys and lost in tamarins
To determine if loss-of-function variation in human and gorilla reflects a general pattern in OAS1 evolution, we next tested OAS1 function from a more diverse sampling of primate species. To capture a broad taxonomic and genetic distribution, we cloned OAS1 p46 from five Old World and three New World monkeys and tested their ability to activate human RNase L in yeast. Similar to gorilla, dusky titi OAS1 p46 contains an early stop codon in exon 6, resulting in a smaller protein product ( Figure S1 ).
African green monkey, rhesus macaque, baboon, and dusky titi OAS1 robustly activate human RNase 
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To determine the basis of the loss of 2-5A synthesis by saddleback tamarin OAS1, we first performed pairwise amino acid alignments to identify possible mutations in conserved active-site residues. A short helical turn motif (p-loop) plays an important role in catalysis through an interaction with the substrate nucleotides 11, 27 . Remarkably, saddleback tamarin OAS1 has three mutations in p-loop residues otherwise strictly conserved in mammals (S63F, S74I and D77N) ( Figure 5A ). Notably, residue 77 is one of three catalytic aspartates that coordinate with Mg 2+ ions to facilitate catalysis. In addition, serine 74, which hydrogen bonds with the b-phosphate of the donor ATP, is replaced with a hydrophobic phenylalanine in tamarin. Finally, like the hypomorphic gorilla OAS1 allele, tamarin OAS1 independently acquired a mutation at residue 130 (arginine to histidine), additionally altering its interaction with the acceptor ATP. Thus, saddleback tamarin OAS1 contains multiple debilitating mutations in conserved substrate interacting and catalytic residues critical for 2-5A synthesis.
To chart the evolutionary history of OAS1 loss-of-function in tamarins, we PCR amplified and sequenced OAS1 exons 1-6 from genomic DNA of the closely related mustached tamarin. Mustached tamarin shares mutations in noncatalytic residues (S63F, S74I, and R130H) but has an intact aspartate triad, similar to a partial sequence available from the related Midas tamarin 34 (Figure 5A ). We next tested whether mustached tamarin OAS1 retains residual 2-5A synthesis activity compared to saddleback tamarin. Yeast expressing saddleback or mustached tamarin OAS1 and human RNase L, however, display no growth arrest ( Figure 5B ), indicating a lack of activity by both species.
Furthermore, purification ( Figure S3C ) and visualization of enzymatic activity in vitro revealed no 2-5A production above background from either species ( Figure 5C ). Finally, we investigated whether tamarin OAS1 might preferentially activate tamarin RNase L through another mechanism. Although saddleback tamarin RNase L also displays lowered activity than human RNase L, it is not activated by tamarin OAS1 in yeast ( Figure S5 ). Thus, evolution of OAS1 in the tamarin lineage involved several inactivating mutations in conserved substrate coordinating residues 63, 74, and 130 in a common ancestor, and the subsequent loss of catalytic aspartate 77 in saddleback tamarins. 
DISCUSSION
Robust immune defenses provide clear benefits to host fitness yet can also exact great costs. Our discovery of repeated and independent debilitating mutations in primate OAS1 reveals distinct mechanisms for balancing the antiviral benefits and deleterious costs of 2-5A synthesis. These findings also highlight how evolution of innate immunity can be constrained by deleterious outcomes of cytotoxic defense mechanisms.
Previous studies on the impact of altering the OAS/RNase L pathway in healthy and infected animals revealed contrasting outcomes consistent with evolutionary compromises. Mice lacking RNase L exhibit greatly increased susceptibility to infection with multiple viruses 35, 36 , supporting a fundamental role for the OAS/RNase L pathway in immunity. In the absence of infection, however, RNase L deficient mice display significantly increased longevity, potentially due to the lack of chronic low level activation of OAS proteins by cellular dsRNAs 37 . Indeed, RNA extracted from various cell types weakly activates OAS1 in vitro 38 , consistent with detectible 2-5A in uninfected tissues 39 . In addition, recent work demonstrated that cellular RNAs activate OAS proteins in the absence of RNA editing by ADAR1 12 .
Lineage-specific increases in the repertoire of cellular RNAs that activate OAS1 could therefore account for the benefit of forfeiting 2-5A synthesis in some species. OAS2 and OAS3, which have distinct dsRNA recognition patterns 40 , provide additional means of RNase L activation, potentially alleviating the loss of OAS1 activity during infection.
Despite recovering several OAS1 loss-of-function alleles in this study, we did not find species lacking the potential to encode OAS1, for example through mutations resulting in premature stop codons precluding the production of the core enzyme. Recurrent, and even compound, mutations in critical substrate binding and catalytic residues in otherwise intact proteins is consistent with a role for OAS1 beyond 2-5A synthesis. Our findings support an evolutionarily conserved role for RNase L-independent antiviral functions for OAS1 that have been proposed in other studies 41, 42 .
Genes encoding immune functions are rich with genetic variation in humans 43 . In some cases, common genetic variants in key mediators of cellular immunity lead to partial or complete loss of protein function and can also be associated with disease. The human OAS1 variant associated with lower in vivo 2-5A levels is also associated with increased risk of infection with West Nile virus 44 and development of Sjörgens syndrome 33 , an autoimmune disease associated EBV and CMV infection. Despite these risks, the allele resulting in production of unstable OAS1 isoforms rose to near fixation in ancient African populations, proceeded by reintroduction of the ancestral high activity allele via introgression from Neandertals to non-African populations [45] [46] [47] . Our identification of multiple independently evolved loss-offunction OAS1 alleles in nonhuman primates is consistent with a common underlying evolutionary pressure frequently favoring lowered OAS activity in humans and nonhuman primates alike.
Similar pressures might favor loss of function in other immunity genes as well. For example, a common human variant of STING, a central component of several viral DNA sensing pathways, results in decreased IFN-b production in response to viral DNAs 48, 49 (but also see 50 ) . The recent description of dampened STING signaling in bats further highlights how selection can favor variants that decrease immune responses to accommodate host biology in specific lineages 51 . Taken in isolation, the prevalence of alleles compromising defense functions is difficult to explain. When considered in a broader context, our findings illustrate how evolutionary forces can act on individual proteins to repeatedly select for diminished immune functions across species.
METHODS
Cloning of OAS1 and RNase L cDNAs
Total RNA was isolated from primate cell lines (quick-RNA miniprep, Zymo Research) followed by preparation of cDNA (Superscript III First-Strand Synthesis kit, ThermoFIsher scientific). Unless otherwise noted, cell lines were obtained from Coriell Cell Repositories ( Figure S1 ; Genbank accession: MH188449-MH188461). OAS1 and RNase L cDNAs were PCR amplified from cDNA using primers indicated in Table S2 . Mustached tamarin OAS1 p46 exons 1-6 were PCR amplified and sequenced directly from genomic DNA. The assembled mustached tamarin OAS1 coding sequence was synthesized by Life Technologies. The human OAS1 p44 and p52 splice variant sequences were synthesized by Life Technologies based on sequences deposited in genbank. OAS1 and RNase L variants were cloned into the yeast CEN Gal10/Gal1 dual expression plasmid pBM272. Human OAS1 splice variants were cloned into vector pcDNA6 for mammalian cell expression. OAS1 was cloned via EcoRI/NotI restriction sites, and RNase L through BamHI sites introduced by PCR primers. C-terminally hemagglutinin tagged Us11 (Us11-HA) was codon optimized for budding yeast and synthesized by Life Technologies (based on Genbank YP_009137147.1.
Yeast growth assays
Yeast strain w303 was used in all experiments in this study. Standard techniques were used for culturing and transformation of yeast. Strains were generated by transformation of EcoRV linearized vector pRS405 containing either an empty site (-Us11) or HA-Us11 (+Us11), resulting in integration at the leu2 locus. Yeast strains were transformed with pBM272 containing OAS1/RNase L variants.
Transformants were grown in S -leu -ura liquid media containing 2% glucose overnight and washed before plating. Tenfold serial dilutions were prepared (OD600 3.0, 0.3, 0.03, 0.003) and a multichannel pipette was used to plate 2.3 µl of each dilution on 2% glucose or 2% galactose medium. Unless otherwise noted, glucose plates were imaged after 24 h of growth, galactose plates after 48 h of growth.
RNA integrity analysis
Transformed yeast were grown to log phase in 2% raffinose S -leu -ura growth medium, followed by induction with 2% galactose for 6 h. Total RNA was extracted using a YeaStar RNA kit (Zymo research) and quantified. RNA integrity was assessed using an RNA ScreenTape assay with the Agilent TapeStation instrument.
Western Blotting
Transformed yeast were grown to log phase in 2% raffinose S -leu -ura growth medium, followed by induction with 2% galactose for 6 h. Cell lysates containing equal amounts of yeast were prepared by treatment with 0.1 M NaOH for 
Mammalian OAS1 alignment
The following OAS1 coding sequences were retrieved from genbank for multialignment: human (Homo 
Generation of Chimeric and mutated OAS1 proteins
Human-gorilla OAS1 chimeras were generated using PCR stitching. Overlapping PCR products were generated and gel purified. 50ng of each PCR product was then added to a new PCR reaction and allowed to anneal and extend for 12 cycles before addition of primers to generate full length chimeric OAS1 coding sequences. Plasmids encoding human OAS1 R130C, gorilla OAS1 C130R , and RNase L H672A were generated by site directed mutagenesis.
Primate OAS Isoform Purification
Human and other primate OAS isoforms were PCR amplified and cloned into a custom pET vector optimized for expression of an N-terminally tagged 6×His-MBP fusion protein, and proteins were expressed and purified from BL21(DE3) RIL E. coli as previously described 52 . Briefly, competent cells already containing the pRARE2 tRNA plasmid (Agilent) were transformed with OAS expression plasmid and grown in 2 × YT media at 37°C to an OD600 of ~0.6 before cooling on ice for 15 min, induced with 0.5 mM IPTG and incubated with shaking at 16°C for ~18 h. Cell pellets were re-suspended in lysis buffer (20 mM HEPES-KOH pH 7.5, 400 mM NaCl, 10% glycerol, 30 mM Imidazole, 1 mM DTT), lysed by sonication, and protein was isolated from clarified lysate using Ni-NTA resin (Qiagen) and gravity-flow chromatography. Resin was washed with lysis buffer supplemented to 1 M NaCl to remove bound nucleic acid, and MBP-OAS protein was eluted with lysis buffer supplemented to 300 mM Imidazole. MBP-OAS proteins were diluted to 50 mM Imidazole and 5% glycerol and concentrated to ~30 mg ml -1 prior to overnight digestion with Tobacco Etch Virus protease at 4°C. Digested protein was separated from MBP and protease using a 5 ml Ni-NTA column (Qiagen) and subsequently purified by Superdex 75 16/60 size-exclusion chromatography in gel-filtration buffer (20 mM HEPES-KOH pH 7.5, 250 mM KCl, 10% glycerol, 1 mM TCEP-KOH). Purified OAS was concentrated to ~10 mg ml -1 , flash-frozen in liquid nitrogen and stored at −80°C for biochemical experiments. MBP-tagged human OAS1 splice isoforms and MBPtagged mustached tamarin and saddleback tamarin OAS homologs were purified using identical conditions, except proteins were dialyzed into storage buffer (20 mM HEPES-KOH pH 7.5, 250 mM KCl, 10% glycerol, 1 mM TCEP-KOH) overnight at 4°C immediately following Ni-NTA elution and directly stored without tag removal or gel-filtration purification.
OAS Enzymatic Assay
Purified recombinant OAS enzyme was incubated in reaction buffer ( Decreased signal from tamarin OAS1 may be due to lower expression level or lowered antibody reactivity. 
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